favezelimab + pembrolizumab + oxaliplatin + leucovorin + fluorouracil

This combination consists of **favezelimab** (an anti-LAG-3 monoclonal antibody), **pembrolizumab** (an anti–PD-1 monoclonal antibody), **oxaliplatin** (a platinum-based cytotoxic chemotherapeutic), **leucovorin** (folinic acid, a biomodulator enhancing the effect of fluorouracil), and **fluorouracil** (a pyrimidine analog antimetabolite chemotherapeutic). The combination targets both **immune checkpoints** and **tumor cell proliferation**: favezelimab and pembrolizumab act by blocking LAG-3 and PD-1, respectively, thereby restoring and enhancing T-cell antitumor function, while oxaliplatin, leucovorin, and fluorouracil together disrupt DNA synthesis and promote cytotoxicity against rapidly dividing cancer cells. Combination immunotherapy (LAG-3 + PD-1 blockade) is being investigated in metastatic colorectal cancer and other advanced cancers, typically in the setting of cases refractory to first-line treatment[1][2][3]. Oxaliplatin, leucovorin, and fluorouracil are established backbone agents (e.g., FOLFOX regimen) in colorectal cancer and gastrointestinal cancers. This specific investigational regimen is being studied in trials of microsatellite stable metastatic colorectal cancer.